Indications
Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Composition
- Active substance
- pemigatinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Pemazyre
- Active substance
- pemigatinib
- ATC code
- L01EN02
- Therapeutic area
- Cholangiocarcinoma
- Marketing authorisation holder
- Incyte Biosciences Distribution B.V.